Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case of cross-reactivities, CAR T cells may also attack...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachmann, Dominik, Aliperta, Roberta, Bergmann, Ralf, Feldmann, Anja, Koristka, Stefanie, Arndt, Claudia, Loff, Simon, Welzel, Petra, Albert, Susann, Kegler, Alexandra, Ehninger, Armin, Cartellieri, Marc, Ehninger, Gerhard, Bornhäuser, Martin, von Bonin, Malte, Werner, Carsten, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800918/
https://www.ncbi.nlm.nih.gov/pubmed/29484126
http://dx.doi.org/10.18632/oncotarget.23556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800918/
https://www.ncbi.nlm.nih.gov/pubmed/29484126
http://dx.doi.org/10.18632/oncotarget.23556

Ejemplares similares